Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: How Do You Strategize Treatment Planning for EGFR-Mutated and ALK-Rearranged Patients?

Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: How Do You Strategize Treatment Planning for EGFR-Mutated and ALK-Rearranged Patients? is organized by Physicians' Education Resource, LLC (PER).

Release Date: August 30, 2019
Expiration Date: August 30, 2020

Target Audience:
This educational activity is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
In the management of non–small cell lung cancer (NSCLC), oncologists face a broad array of choices in the first-line setting of patients with advanced disease. With rapid growth in the field over the past 5 years, oncologists may face difficulties and gaps in evidence when determining the appropriate approach to patients with EGFR mutations and ALK rearrangements in the frontline and later-line settings. This comprehensive online program, featuring perspectives on key issues in management from David R. Gandara, MD; Roy S. Herbst, MD, PhD; Robert C. Doebele, MD, PhD; and Justin F. Gainor, MD, will enable rapid implementation of appropriate testing strategies for NSCLC, up-to-date approaches to sequencing therapies in patients with NSCLC, and the best evidence-based strategies for adverse event identification and management.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe appropriate testing strategies that impact the development of optimal NSCLC treatment plans in the first line and beyond.
• Describe newly approved and emerging targeted therapeutic strategies that can be administered in the clinical management of NSCLC with EGFR or ALK molecular aberrations.
• Apply sequential targeted approaches to treat NSCLC with EGFR or ALK molecular aberrations.
• Develop and implement strategies to monitor responses and mitigate treatment-related toxicities.

Additional details will be posted as soon as information is available.